Thank you AU. I passed on the post to a Type 1 diabetic so they can do their own evaluation. I have not met you but I am guessing you are older (and wiser). Which means that younger diabetics will react even better.
That's very good news. PPS going up while short volume going up. Poor suckers pouring in cheap shares being bought up easily.
I agree Opc. All we have is circumstantial evidence. A lot of it but no direct evidence. agreed. When you think about it, product development is all based on circumstantial evidence. Nobody really knows for sure if Afrezza causes cancer in the long run. Yet billions and billions are invested on a lot of new drugs relying on circumstantial evidence. For many decades no one could disprove Einstein's theories based entirely on figments of his imagination. Yes, we don't have direct information whether SNY was the "partner" mentioned in the past. But evidence points to it. Circumstantial evidence.
OPC, I am not certain if it was an example but the words Lantus-Afreeza combo appears several times in the patent. There was a long discussion about that in this MB years ago. I don't believe they publish new filings until they are approved. That was true in the past but I may be outdated. But you would think that if they filed a Lantus/AFrezza combo patent that they should also file one for Toujeo/Afrezza unless they are very confident they don't need a patent because they "own" both.
OK here's one fact you can't argue - the Lantus/Afrezza Combo Patent. It takes two years to get a patent approvedand about 6 months to prepare a patent. The patent was approved in 2010. So you are looking at 2007 collaboration to acquire the patent. Is that enough proof for you?
"but odds are those statements aren't necessarily accurate." - They are factual statements. Ask OPC for a fact check.
mike, not only did SNY ask that Medtone be replaced, at about the same time they sold their EU rights for Exubera to Pfizer. This was in realization that Exubera, even if Pfizer kept selling it would just be wiped out by Afrezza. Sanofi also bought the former Exhubera plant in France. WHY? If they have no powdered insulin what would they need a plant designed for producing powdered insulin? All that are indicators of their long term commitment to Afrezza.
dango, the price is suppose to be comparable as the pens. In any case, the price to the patient is just the co-pay required by their insurance company. Didn't Obamacare require that everyone have insurance? No one will be paying cash or retail price. So for all practical purpose, the question should be, can the patient afford their co-pay which is the same as the pen.
very cool. It is available for $285.54 in the nearest Target, CVS, WAl-Mart, and even a local pharmacy that has only 1 store. It is all over the place now. You should try it if you have any doubt. It is available now at your nearest drugstore.
That is correct. It is not available in India yet. Try calling pharmacies in the U.S.
How much does Afrezza cost?
According to the manufacturer, Afrezza prices have not yet been finalized but will likely be comparable to the current rapid-acting insulin analog pens.
Below are examples of AWPs (Average Wholesale Prices) for reference:
NovoLog FlexPen (Insulin Aspart) 100 units/ml (3ml): $85.70
Humalog KwikPen (Insulin Lispro) 100 units/ml (3ml): $85.46
Apidra SoloStar (Insulin Glulisine) 100 units/ml (3ml): $72.63
Makes sense. MNKD earned the $50M milestone by delivering the inventory needed for the launch. so we know that Afrezza is already at the distributors and they are ready to deliver to pharmacies is not already delivering. Pretty soon we'll be seeing people with the Afrezza device around their neck doing selfies - Coming Very Soon.
yeah right Mike, France has 75% taxation for the rich, That's why the former CEO moved his office to Boston. I's sure "SNY will never want the U.S. tax" - way to go Mike.
you might want to sign up for the automated notice of the launch - Go to MNKD website and there's a notice if you want to receive notification when Afrezza is available sign up for auto notice.
Assuming this is a rollover, they preferred not to buy the stock and pay $15M ($5 X 3M shares) but want to have 3M shares for whatever reason such as a cover for short position or simply wanting a windfall if pps goes up.
Just one more comment. MNKD is not doing anything that all manufacturers are doing. Prices are confidential. The only publicly known prices are WAC, which fortunately nobody pays unless you have no insurance at all and pay cash. Even if you found out what insurers reimburse for the product it is not the true price because of all the complex rebates, admin fees, performance rebates, formulary discounts etc. Even people doing "price and reimbursement" work in the industry do not know how much exactly is a drug reimbursed for. The published WAC price is not a price at all to compare products because it does not take into account any discounts granted in the distribution stream (discount to wholesalers, discounts to pharmacies, rebates, etc.)
megprg, MNKD has repeatedly stated what the price will be - 20% more than current injectible insulin which is consistent with the premium price by the pens. Look up one of the past conferences where the question was asked. Since 2011, MNKD has come through with it's statements. Why would this be different? The one thing where MNKD's credibility was shot was the 2nd CRL, which unfortunately is not within their control. They honestly believed they will get approved. As a result of the 2nd CRL other promises had to be broken such as "no dilution". But beyond that, there is no reason to believe the price will be other than what they already stated. I can list down all the statements they made that has come through since 2011. But you already know those. So if you want an exact dollar amount, get the Lantus price and increase it by 20% or get the pen price and it is within that vicinity.